Earnings Summary

Charles River Laboratories International’s revenue jumped 8.92% since last year same period to $1059.94Mn in the Q2 2023. On a quarterly growth basis, Charles River Laboratories International has generated 2.97% jump in its revenue since last 3-months.

Charles River Laboratories International’s net profit fell -11.25% since last year same period to $97.02Mn in the Q2 2023. On a quarterly growth basis, Charles River Laboratories International has generated -6.67% fall in its net profits since last 3-months.

Charles River Laboratories International’s net profit margin fell -18.52% since last year same period to 9.15% in the Q2 2023. On a quarterly growth basis, Charles River Laboratories International has generated -9.36% fall in its net profit margins since last 3-months.

Charles River Laboratories International’s earning per share (EPS) estimates for the current quarter stand at 2.74 - a 9.6% jump from last quarter’s estimates.

Charles River Laboratories International’s earning per share (EPS) estimates for the current year stand at 2.74.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Charles River Laboratories International’s return on assets (ROA) stands at 0.05.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Charles River Laboratories International’s return on equity (ROE) stands at 0.16.